Stock listing

Cboe Canada:RVX Resverlogix Corp. Stock

Canadian listing (Cboe Canada) of Resverlogix Corp. · home listing TSX:RVX

Follow Resverlogix Corp. into a list and get an email when it puts out news.

Home listing price · TSX:RVX

$0.075 CAD 0.000 (0.0%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, TSX:RVX

Past year -31.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.075 – $0.075 CADNov 20, 2026
Volume
1,000 sharesNov 20, 2026
Market cap
$25.82M CADAt the close on Nov 20, 2026 · price × 344.3M shares outstanding
52-week range
$0.070 – $0.150 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2,498 CADMedian day 11,500 shares · 8 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Resverlogix Corp. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
TSX:RVX · Home$0.075 CAD0.000 (0.0%)1,000$0.075$0.075$0.075$0.075Close on Nov 20, 2026
OTC:RVXCF$0.048 USD-0.002 (-4.4%)5,968$0.041$0.048$0.041$0.050Close on Nov 20, 2026
Frankfurt:RFS€0.042 EUR0.000 (0.0%)—€0.042€0.042€0.042€0.042Close on Nov 20, 2026
Munich:RFS€0.042 EUR-0.006 (-12.6%)—€0.048€0.048€0.042€0.048Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TSX:RVX · CAD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.0750.0000.0%$0.075$0.075$0.0751,000
$0.075-0.005-6.3%$0.075$0.075$0.07511,000
$0.080+0.005+6.7%$0.080$0.080$0.0800
$0.0750.0000.0%$0.075$0.075$0.075129,000
$0.0750.0000.0%$0.075$0.075$0.07536,000
$0.075-0.005-6.3%$0.075$0.075$0.0757,689
$0.0800.0000.0%$0.080$0.080$0.0800
$0.0800.0000.0%$0.080$0.080$0.0805,000
$0.080+0.005+6.7%$0.075$0.080$0.07570,380
$0.075+0.005+7.1%$0.075$0.080$0.07546,600
$0.070-0.010-12.5%$0.080$0.080$0.070216,400
$0.080+0.005+6.7%$0.080$0.080$0.07064,011
$0.0750.0000.0%$0.080$0.080$0.0752,850
$0.0750.0000.0%$0.075$0.075$0.0754,000
$0.075-0.005-6.3%$0.080$0.080$0.07542,025
$0.0800.0000.0%$0.080$0.080$0.07520,000
$0.080+0.005+6.7%$0.080$0.080$0.0800
$0.075-0.005-6.3%$0.075$0.075$0.0753,000
$0.080-0.010-11.1%$0.080$0.080$0.08050,178
$0.0900.0000.0%$0.090$0.090$0.0900
$0.090+0.010+12.5%$0.090$0.090$0.09023,300
$0.0800.0000.0%$0.080$0.080$0.08048,000
$0.080-0.010-11.1%$0.090$0.090$0.0805,000
$0.090+0.010+12.5%$0.090$0.090$0.0903,000
$0.080-0.010-11.1%$0.090$0.090$0.08063,300
$0.0900.0000.0%$0.090$0.090$0.0903,000
$0.090+0.005+5.9%$0.090$0.090$0.0903,500
$0.085-0.005-5.6%$0.085$0.085$0.08530,256
$0.0900.0000.0%$0.090$0.090$0.0902,000
$0.0900.0000.0%$0.090$0.090$0.0903,200
$0.0900.0000.0%$0.090$0.090$0.0907,200
$0.0900.0000.0%$0.090$0.090$0.08091,100
$0.0900.0000.0%$0.090$0.090$0.0905,800
$0.0900.0000.0%$0.090$0.090$0.09090,500
$0.0900.0000.0%$0.090$0.090$0.09056,200
$0.090-0.005-5.3%$0.090$0.090$0.09033,400
$0.095-0.005-5.0%$0.095$0.095$0.09061,178
$0.100-0.010-9.1%$0.100$0.100$0.0958,000
$0.110+0.020+22.2%$0.090$0.120$0.090113,900
$0.0900.0000.0%$0.090$0.090$0.0900
$0.0900.0000.0%$0.100$0.100$0.09035,700
$0.0900.0000.0%$0.090$0.090$0.09031,600
$0.0900.0000.0%$0.090$0.090$0.0901,100
$0.0900.0000.0%$0.090$0.090$0.0900
$0.0900.0000.0%$0.090$0.090$0.0900
$0.0900.0000.0%$0.090$0.090$0.09080,600
$0.0900.0000.0%$0.090$0.090$0.0902,600
$0.0900.0000.0%$0.100$0.100$0.09016,000
$0.0900.0000.0%$0.100$0.100$0.09075,000
$0.090-0.010-10.0%$0.100$0.100$0.09042,500
$0.1000.0000.0%$0.090$0.100$0.0904,500
$0.1000.0000.0%$0.100$0.100$0.09020,100
$0.1000.0000.0%$0.100$0.100$0.100600
$0.1000.0000.0%$0.100$0.100$0.1001,600
$0.1000.0000.0%$0.100$0.100$0.09064,000
$0.1000.0000.0%$0.090$0.100$0.09012,000
$0.1000.0000.0%$0.100$0.100$0.10031,300
$0.1000.0000.0%$0.100$0.100$0.100500
$0.1000.0000.0%$0.100$0.100$0.1000
$0.100-0.010-9.1%$0.100$0.110$0.10016,800
$0.110+0.010+10.0%$0.110$0.110$0.1101,000
$0.1000.0000.0%$0.100$0.110$0.10020,500
$0.1000.0000.0%$0.100$0.100$0.10033,700
$0.1000.0000.0%$0.100$0.100$0.1004,000
Ticker
Cboe Canada:RVX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Cboe Canada
Currency
CAD

What changed lately

Latest news

All Resverlogix Corp. news

Resverlogix Corp. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
12 in the last 12 months · 231 in all · newest Sep 10, 2026 · oldest 2007
Decks
18 decks · latest Jun 25, 2026

Where Resverlogix Corp. is listed

ListingExchangeCountryCurrency
TSX:RVX · Home listingTSXCanadaCAD
LS Exchange:A0DP7LLS ExchangeGermanyEUR
OTC:RVXCFOTCUnited StatesUSD
Lang & Schwarz:A0DP7LLang & SchwarzGermanyEUR
Frankfurt:RFSFrankfurtGermanyEUR
LSE:0VF9LSEUnited KingdomCAD
Munich:RFSMunichGermanyEUR
Cboe Canada:RVX · This pageCboe CanadaCanadaCAD
Stuttgart:RFSStuttgartGermanyEUR

Valuation

Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$137.0M CAD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P/TSX Composite
0.26

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Resverlogix Corp. · TSX:RVXUS$18.01MUS$95.55Mn/an/an/an/an/an/a0.26
IGC Pharma, Inc. · AMEX:IGCUS$19.60MUS$19.19Mn/an/an/a3.0×n/a0.0×1.09
Provectus Biopharmaceuticals, Inc. · OTC:PVCTUS$19.12MUS$18.94Mn/an/an/an/an/an/a-0.21
LeonaBio, Inc. · NASDAQ:LONAUS$19.03M−US$12.82Mn/an/an/a1.2×n/a0.0×1.04
Cocrystal Pharma, Inc. · NASDAQ:COCPUS$18.30MUS$14.69Mn/a33.8×n/a6.8×n/a0.5×1.21
Syntara Limited · ASX:SNTUS$18.20MUS$9.23Mn/a2.0×n/a1.7×−129.8%0.0×n/a
Marker Therapeutics, Inc. · NASDAQ:MRKRUS$18.17MUS$9.13Mn/a4.9×n/a1.7×−461.1%0.0×1.49
SynCore Biotechnology Co., Ltd. · TPEX:4192US$16.80MUS$12.38Mn/a15.6×n/a2.5×−178.5%0.0×n/a
Initiator Pharma A/S · OMXSTO:INITUS$16.74MUS$15.65Mn/an/an/a13.4×n/a1.1×n/a
Neurotech International Ltd. · ASX:NTIUS$16.63MUS$15.06Mn/an/an/a41.1×n/a0.0×n/a
Akari Therapeutics PLC · NASDAQ:AKTXUS$16.41MUS$10.66Mn/an/an/a0.9×n/a0.0×1.49
Median of the othersUS$18.19MUS$13.53M10.2×2.5×−178.5%0.0×1.15

Team and board

Officers

OfficerRole
Donald J. McCaffreyPresident & Chief Executive Officer
Brad CannChief Financial Officer
Michael SweeneySenior Vice President, Clinical Development
Ravi JahagirdarVice President, Pharmacology, Toxicology & Safety
Ewelina KulikowskiChief Scientific Officer

Board

DirectorRole
Donald J. McCaffreyPresident & Chief Executive Officer
Bradley GlassDirector
Kenneth J. ZuerblisBoard Member

Events

QuarterResultsShare move
Quarter to Sep 30, 2026Nov 12, 2026 · After close0.0%
Q2 2026Aug 13, 2026 · After close0.0%
Q1 2026May 14, 2026 · After close0.0%
Q4 2025Mar 31, 2026 · After close−9.1%
Q3 2025Nov 12, 2025 · After close0.0%
Q2 2025Aug 14, 2025 · After close0.0%
Q1 2025Jun 4, 2025 · After close−20.0%
Q3 2024Nov 7, 2024 · After close0.0%
Q1 2024May 14, 2024 · After close+8.3%
Quarter to Jan 31, 2024Mar 31, 20240.0%
All 20 quarters
QuarterResultsShare move
Quarter to Oct 31, 2023Dec 31, 20230.0%
Quarter to Jul 31, 2023Sep 30, 20230.0%
Quarter to Apr 30, 2023Jun 30, 20230.0%
Quarter to Jan 31, 2023Mar 31, 2023+6.9%
Quarter to Oct 31, 2022Dec 31, 20220.0%
Quarter to Jul 31, 2022Sep 30, 20220.0%
Quarter to Apr 30, 2022Jun 30, 2022−7.8%
Quarter to Jan 31, 2022Mar 31, 2022−4.3%
Quarter to Oct 31, 2021Dec 31, 2021−2.0%
Quarter to Jul 31, 2021Sep 30, 2021+2.0%

Open Events

Decks

DeckKindSlidesDate
Shareholder Meeting (June 2026)Shareholder meeting14 slidesJun 25, 2026
Shareholder Meeting (June 2023)Shareholder meeting39 slidesJun 20, 2023
Shareholder Meeting (June 2022)Shareholder meeting18 slidesJun 20, 2022
Corporate Update (December 2021)Corporate update25 slidesDec 16, 2021
Shareholder Meeting (June 2021)Shareholder meeting16 slidesJun 22, 2021
Investor Presentation (February 2021)Investor deck18 slidesFeb 4, 2021
CTAD 2021Conference12 slides2021
Technical Presentation (2021)Technical6 slides2021
Technical Presentation (November 2020)Technical17 slidesNov 16, 2020
Technical Presentation (July 2020)Technical57 slidesJul 23, 2020
All 18 decks
DeckKindSlidesDate
Corporate Update (June 2020)Corporate update9 slidesJun 10, 2020
ERA-EDTA 2020Conference25 slidesJun 9, 2020
ERA-EDTA 2020Conference25 slidesJun 9, 2020
Technical Presentation (November 2019)Technical63 slidesNov 18, 2019
Investor Presentation (March 2019)Investor deck31 slidesMarch 2019
Investor Presentation (January 2019)Investor deck31 slidesJan 7, 2019
Investor Presentation (December 2018)Investor deck31 slidesDecember 2018
Investor Presentation (November 2018)Investor deck30 slidesNovember 2018

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue437.5K476.7K729.5K00
Gross profit-437.5K-476.7K-729.5K00
Research and development2.77M2.85M3.25M5.51M4.51M6.40K15.8M32.3K37.8M29.9M
Selling, general and administrative1.96M1.79M3.02M6.94M11.1M5.33M6.78M6.51K4.07M4.27M
Operating income-5.20M-6.37M-6.26M-12.7M-16.0M-14.6K-22.6M-38.7K-30.9M-34.1M
Depreciation and amortization437.5K348.0K716.0K1.01M1.11M1.03M1.03M356.0K358.0K377.0K
EBITDA-4.77M-6.02M-5.55M-11.7M-14.9M1.01M-21.6M317.3K-30.5M-33.8M
Interest expense4.33M4.20M1.87M1.63M727.0K2.98M3.57M5.63M5.45M7.03M
Income before tax-7.94M-7.62M-16.7M-3.59M-24.8M2.50K118.1M-162.8K-58.3M-46.1M
Income tax-39.7K14.0K15.0K18.0K12.0K3227.0K2947.0K83.0K
Net income-7.90M-7.63M-16.7M-3.61M-24.8M2.46K118.0M-162.8K-58.3M-46.2M
Earnings per share, basic-0.03-0.03-0.06-0.01-0.100.000.53-0.00-0.42-0.44

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents107.8K99.0K5.00K40.0K6.00K87.0K4.00K7.69M121.0K1.35M
Receivables910.3K346.6K104.0K323.0K310.0K848.0K920.0K978.0K216.0K245.0K
Inventory434.2K996.0K300.0K2.37M2.45M584.0K1.55M1.16M3.06M3.34M
Current assets1.60M1.54M564.0K2.89M2.95M1.94M3.18M10.6M4.04M5.65M
Property, plant and equipment0426.0K1.04M1.46M1.96M350.0K468.0K628.0K
Total assets7.93M7.34M6.57M8.12M9.98M10.7M11.4M16.3M8.28M10.9M
Accounts payable18.2M4.30M14.5M14.1M8.70M6.94M7.88M8.19M22.2M12.2M
Current liabilities44.0M26.3M26.9M22.7M17.4M11.8M28.7M86.6M38.0M69.7M
Long-term debt61.9M53.3M43.7M137.4M54.0M42.7M
Total debt72.8M82.0M9.91M6.49M7.04M996.0K13.2M14.8M708.0K48.6M
Total liabilities96.7M89.1M81.0M67.4M69.9M50.6M75.5M224.0M92.0M112.4M
Shareholders' equity-88.8M-81.7M-74.5M-59.3M-59.9M-39.9M-64.1M-207.7M-83.7M-101.6M
Shares outstanding285.1M276.6M270.0M254.4M239.9M235.0M221.4M202.7M137.7M105.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-3.73M-3.89M-2.51M-3.54M-8.02M-4.40K-17.3M-48.8M-25.1M-22.7M
Capital spending-9.16K-472.0K-448.0K-450.0K-877.0K-13-500.0K-622.0K-537.0K-559.0K
Free cash flow-3.73M-4.36M-2.96M-3.99M-8.90M-4.41K-17.8M-49.5M-25.7M-23.2M
Cash from investing-660.4K-377.0K-516.0K-473.0K-833.0K-426-576.0K-731.0K-360.0K-652.0K
Cash from financing4.39M4.36M2.99M4.06M8.81M4.95K10.2M57.1M23.3M-2.38M
Dividends paid000000000
Share buybacks278.0K4.70M4.02M4.04M16.4M47.6M83.2M250.0K
Change in cash4.12K94.0K-35.0K34.0K-81.0K-7.68K-7.68M7.57M-1.23M-26.8M

Open Financials

Cap table

Built by 6ix from Resverlogix Corp.’s releases

Common shares
344,286,709
Fully diluted
347,186,709

Fully diluted

LineShares
Common shares344,286,709
Options and RSUs2,900,000

Warrants and options

Lot
Stock options · C$0.09 · expiry not stated
RSUs · expiry not stated
Stock options · C$0.09 · expiry not stated
RSUs · expiry not stated

Share count over time

CountShares
Nov 22, 2026344,286,709

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
A. Brad CannChief Financial Officer · Since at least Apr 11, 2026
Bradley GlassDirector · Since at least Nov 18, 2025
Donald J. McCaffreyPresident & Chief Executive Officer · Since at least Apr 11, 2026
Ewelina KulikowskiChief Scientific Officer · Since at least Sep 10, 2026
Kenneth J. ZuerblisBoard Member · Since at least Jun 26, 2026
Michael SweeneySenior Vice President, Clinical Development · Since at least Nov 5, 2026
Ravi JahagirdarVice President, Pharmacology, Toxicology & Safety · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Resverlogix Corp.